We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microscopic Hematuria an Unreliable Indicator of Bladder Cancer

By LabMedica International staff writers
Posted on 04 Feb 2013
A study found that microscopic hematuria does not necessarily mean cancer, and has led to a new model to predict renal and bladder cancer risk better.

Blood found in urine that cannot be seen by the naked eye does not necessarily indicate the presence of cancer, according to a Kaiser Permanente Southern California (Gardena, CA, USA) study published in the January 11, 2013, online version of the journal Mayo Clinic Proceedings. More...
Tests routinely done on patients with this condition could be avoided and has led to the creation of a screening tool to better diagnose certain types of cancers.

The study examined the electronic health records of more than 4,000 patients with microscopic hematuria who were members of Kaiser Permanente health plans in Southern California, Northern California, and the Pacific Northwest between January 2009 and August 2011. The study found that an extremely small proportion of patients with microscopic hematuria were subsequently discovered to have cancer. Among the 4,414 patients who were evaluated for the condition, only 2.3% were diagnosed with bladder cancer and only 0.2% had a pathologically confirmed diagnosis of renal cancer.

Pathology reports were reviewed for all patients with cancer diagnoses. A total of 50 cancers (44 bladder and 6 renal) were confirmed in the test cohort and 61 cancers (56 bladder and 5 renal) in the validation cohort. In the test cohort, 5 of 55 neoplasms were benign on the final pathology report, and 1 patient with a 1.7-cm, enhancing renal lesion elected close observation and was counted as having stage T1 cancer. In the validation cohort, 56 of 59 bladder cancers were confirmed as were 5 of 7 renal cancers (2 renal lesions were benign hemorrhagic renal cysts). The overall cancer detection rate was 1.9% in the test cohort (50 of 2630 patients) and 3.4% for the validation cohort (61 of 1784 patients).

Overall, 100 bladder cancers were diagnosed among 4414 patients evaluated (2.3%), and only 11 renal cancers were pathologically confirmed (0.2%).

It is probable that patients with microscopic hematuria, especially those under 50 years of age and with no history of gross hematuria, may not benefit from further evaluation, and therefore could avoid routine tests that contain unnecessary risks such as radiation exposure from CT scans and invasive endoscopy.

“This study provides scientific data that confirms what others have suspected—that microscopic hematuria is an unreliable indicator of renal or bladder cancer,” said study lead author Ronald K. Loo, MD, and regional chief of urology for the Southern California Permanente Medical Group. “This suggests that a large number of follow-up examinations of patients with asymptomatic microscopic hematuria, which often includes radiologic and invasive procedures, could be safely avoided.”

Related Links:
Kaiser Permanente Southern California



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
HPV Test
Allplex HPV28 Detection
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.